Royalty Pharma plc
RPRX
$60.85
-$1.07-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.54B | 2.44B | 2.38B | 2.35B | 2.31B |
| Total Other Revenue | -- | 1.00M | 1.00M | 1.00M | 1.00M |
| Total Revenue | 2.54B | 2.44B | 2.38B | 2.35B | 2.31B |
| Cost of Revenue | 105.97M | -366.18M | -295.84M | -154.91M | -394.65M |
| Gross Profit | 2.43B | 2.81B | 2.67B | 2.50B | 2.70B |
| SG&A Expenses | 638.85M | 721.20M | 676.11M | 554.10M | 492.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 983.46M | 796.30M | 832.27M | 801.19M | 449.67M |
| Operating Income | 1.55B | 1.64B | 1.55B | 1.55B | 1.86B |
| Income Before Tax | 1.35B | 1.36B | 1.33B | 1.31B | 1.67B |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.35K | 1.36K | 1.33K | 1.31K | 1.67K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -534.87M | -531.73M | -553.25M | -537.67M | -644.05M |
| Net Income | 815.00M | 829.29M | 773.95M | 767.96M | 1.02B |
| EBIT | 1.55B | 1.64B | 1.55B | 1.55B | 1.86B |
| EBITDA | 1.56B | 1.65B | 1.01B | 654.92M | 225.49M |
| EPS Basic | 1.77 | 1.80 | 1.68 | 1.65 | 2.19 |
| Normalized Basic EPS | 0.56 | 0.74 | 0.57 | 0.66 | 0.87 |
| EPS Diluted | 1.76 | 1.80 | 1.67 | 1.64 | 2.19 |
| Normalized Diluted EPS | 0.44 | 0.58 | 0.45 | 0.53 | 0.69 |
| Average Basic Shares Outstanding | 1.87B | 1.85B | 1.85B | 1.88B | 1.90B |
| Average Diluted Shares Outstanding | 2.23B | 2.23B | 2.26B | 2.29B | 2.32B |
| Dividend Per Share | 0.91 | 0.90 | 0.88 | 0.87 | 0.86 |
| Payout Ratio | 48.96% | 46.71% | 48.87% | 49.17% | 36.76% |